Literature DB >> 8877140

Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

A B Hartman1, L L Van de Verg, C R Mainhart, B D Tall, S J Smith-Gill.   

Abstract

Protective immunity against shigellosis is thought to be determined by the O-antigen side chains of the lipopolysaccharide (LPS) molecule. To study possible common protective epitopes, monoclonal antibodies reacting with Shigella flexneri 2a LPS were generated from BALB/c mice infected ocularly with the virulent serotype 2a strain S. flexneri 2457T and tested against a panel of S. flexneri LPSs by enzyme-linked immunosorbent and immunoblot assays. Four monoclonal antibodies were identified, all of which showed restricted specificity patterns. Three different patterns of reactivity to LPS possessing the 3,4 group antigen were seen: (i) 2a only, (ii) 2a and 5a, and (iii) 2a, 4a, 5a, and Y. These results have implications for designing a Shigella vaccine that will be protective against related serotypes. Electron microscopy studies showed that the monoclonal antibodies bind to the bacterial surface in a patchy pattern, suggesting their potential use for examining the LPS distribution on the surface of the bacteria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877140      PMCID: PMC170411          DOI: 10.1128/cdli.3.5.584-589.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide.

Authors:  D Cohen; M S Green; C Block; R Slepon; Y Lerman
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

2.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.

Authors:  C O Tacket; S B Binion; E Bostwick; G Losonsky; M J Roy; R Edelman
Journal:  Am J Trop Med Hyg       Date:  1992-09       Impact factor: 2.345

4.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Structural studies of Shigella flexneri O-antigens.

Authors:  L Kenne; B Lindberg; K Petersson; E Katzenellenbogen; E Romanowska
Journal:  Eur J Biochem       Date:  1978-11-02

6.  Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.

Authors:  S B Formal; E V Oaks; R E Olsen; M Wingfield-Eggleston; P J Snoy; J P Cogan
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

7.  HeLa cell invasiveness and O antigen of Shigella flexneri as separate and prerequisite attributes of virulence to evoke keratoconjunctivitis in guinea pigs.

Authors:  N Okamura; T Nagai; R Nakaya; S Kondo; M Murakami; K Hisatsune
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

8.  On the serology of Plesiomonas shigelloides.

Authors:  T Shimada; R Sakazaki
Journal:  Jpn J Med Sci Biol       Date:  1978-04

9.  Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.

Authors:  J W Newland; T L Hale; S B Formal
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

10.  Characterization of five Shigella flexneri variant Y-specific monoclonal antibodies using defined saccharides and glycoconjugate antigens.

Authors:  N I Carlin; D R Bundle; A A Lindberg
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

View more
  2 in total

1.  Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Authors:  Robert W Kaminski; K Ross Turbyfill; C Chao; W M Ching; Edwin V Oaks
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

2.  Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.

Authors:  Jisheng Lin; Mark A Smith; William H Benjamin; Robert W Kaminski; Heather Wenzel; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2016-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.